Improving Scientific Rigor of Renal Clinical Endpoints for Sickle Cell Anemia
Purpose
The investigators will attempt to develop a more accurate equation to estimate eGFR in pediatric and adult sickle cell patients
Conditions
- Sickle Cell Disease
- Renal Disease
- Glomerular Disease
Eligibility
- Eligible Ages
- Between 5 Years and 50 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- SCA patients (HbSS and SB0 thalassemia) - Age: 5.0-50.0 at enrollment
Exclusion Criteria
- Recent SCA complication associated with hospitalization (within 30 days) or ED visit (within 14 days) - Current AKI defined as >0.3mg/g increase in SCr from prior visit - Known history of anaphylaxis with contrast agent or known pregnancy
Study Design
- Phase
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
| Pediatric SCA | We will develop a novel eGFR equation in 200 pediatric participants |
|
| Adult SCA | We will develop a novel eGFR equation in 200 adult participants |
|
Recruiting Locations
Birmingham, Alabama 35223
More Details
- Status
- Recruiting
- Sponsor
- University of Alabama at Birmingham
Detailed Description
200 pediatric and 200 adult SCA participants will undergo mGFR using iohexol at baseline and at one year. On the same day, participants will undergo clinical and laboratory variables important for developing an eGFR equation. From baseline data, the investigators will perform a training and validation cohort of biologically relevant predictor variables to develop a novel equation. Then the investigators will compare the novel SCA eGFR equation to the established eGFR equation. From one year data, the investigators will determine the longitudinal concordance between pediatric and adult novel and standard eGFR equations with mGFR and variables that may alter longitudinal inferences. In a subset of 30 adult participants, the investigators will also evaluate the correlation between mGFR using iohexol and a novel measure of mGFR that is more time efficient